Skip to Content

Respironics names new CEO/president

Respironics names new CEO/president

October 6, 2003 MURRYSVILLE, Pa. - The Board of Directors of Respironics announced the appointment of John L. Miclot to the position of president and CEO effective December 1, 2003. Miclot has most recently held the position of chief strategic officer of Respironics and previously served as president of the Homecare Division for three and a half years. He succeeds James W. Liken, who has been president and CEO since August of 1999. Liken will assume the newly created role of vice chairman of Respironics. Liken said the appointment of Miclot as president and CEO is the result of a succession plan that the board of directors and he have been working on for the past several years. “John has done an outstanding job in his various leadership roles since joining Respironics in 1998. He has over two decades of experience in the medical device industry, and has a proven track record of leading successful market-driven strategies,” said Liken. Miclot said the current senior management team will remain, led by Craig Reynolds as chief operating officer and Dan Bevevino as chief financial officer. Commenting on the transition, Respironics founder and Chairman of the Board, Gerald McGinnis said that Liken has done a remarkable job leading Respironics during his tenure as president and CEO over the past four years. “Jim has provided clear direction, created an energy and vibrancy among our associates worldwide, and has built a culture of success that has led the company through 15 consecutive quarters of sales and profit growth. We look forward to his continued contributions on our Board as Vice Chairman,” McGinnis said. “During this same four year period, John Miclot has had significant impact on our success as president of the Homecare Division and then as chief strategic officer. During the last year, John has built a strategic framework for the company that will enable Respironics to implement its initiatives well into the future.”

Comments

To comment on this post, please log in to your account or set up an account now.